Novel non-invasive methods of insulin delivery

Bibliography

• Migdalis IN. Insulin analogs versus human insulin in type 2 diabetes. Diabetes Res Clin Pract 2011;93(Suppl 1):S102-S4
   PubMed Web of Science ®Google Scholar
• Gough SC. A review of human and analogue insulin trials. Diabetes Res Clin Pract 2007;77(1):1-15
   PubMed Web of Science ®Google Scholar
• MannKind Corp. Web Page. Available from: http://www.mannkindcorp.com/ [Last accessed 30 July 2012]
   Google Scholar
• Richardson PC, Boss AH. Technosphere® insulin technology. Diabetes Technol Ther 2007;9(Suppl 1):S65-72
   PubMedGoogle Scholar
• Al-Qadi S, Grenha A, Carrión-Recio D, Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulin-loaded formulations. J Control Release 2012;157(3):383-90
   PubMed Web of Science ®Google Scholar
• Cassidy J, Amin N, Marino M, Insulin lung deposition and clearance following Technosphere® insulin inhalation powder administration. Pharm Res 2011;28(9):2157-64
   PubMed Web of Science ®Google Scholar
• Leone-Bay A, Baughman R, Smutney C, Kocinsky J. Innovation in drug delivery by inhalation. In: Publishing FF, editor. Orally inhaled & nasal drug products: innovations from major delivery system developers. ONdrugDelivery; East Sussex, United Kingdom: 2010. p. 4-7
   Google Scholar
• Angelo R, Rousseau K, Grant M, Technosphere insulin: defining the role of technosphere particles at the cellular level. J Diabetes Sci Technol 2009;3(3):545-54
   PubMedGoogle Scholar
• Potocka E, Cassidy JP, Haworth P, Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. J Diabetes Sci Technol 2010;4(5):1164-73
   PubMedGoogle Scholar
• Leone-Bay A, Grant M. Technosphere® technology: a platform for inhaled protein therapeutics. In: ONdrugDelivery, editor. Pulmonary delivery: innovative technologies breathing new life into inhalable therapeutics. ONdrugDelivery; East Sussex, United Kingdom: 2006. p. 8-11
   Google Scholar
• Marino MT, Cassidy JP. The relationship between two insulin assays used to determine bioequivalence and dose proportionality of AFREZZA® insulin administered using a gen2 inhaler compared to a MedTone inhaler: simulation of clinical trials and actual data. Poster #141-RIA, presented at the Diabetes Technol Soc meeting; 2010
   Google Scholar
• Pfützner A, Mann AE, Steiner SS. Technosphere™/Insulin—a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther 2004;4(5):589-94
   Google Scholar
• Markey KA. MannKind Corp. Update report. Griffin Securities Equities Research; New York: 2011
   Google Scholar
• Steiner S, Pfützner A, Wilson BR, Technosphere/Insulin - proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocr Diab 2002;110(1):17-21
   PubMed Web of Science ®Google Scholar
• Pfützner A, Forst T. Pulmonary insulin delivery by means of the Technosphere™ drug carrier mechanism. Expert Opin Drug Deliv 2005;2(6):1097-106
   PubMedGoogle Scholar
• Rosenstock J, Lorber DL, Gnudi L, Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet 2010;375(9733):2244-53
   PubMed Web of Science ®Google Scholar
• Potocka E, Baughman R, Derendorf H. Population pharmacokinetic model of human insulin following different routes of administration. J Clin Pharmacol 2011;51(7):1015-24
   PubMed Web of Science ®Google Scholar
• Heinemann L. Variability of insulin action: does it matter? Insulin 2008;3(1):37-45
   Google Scholar
• Rave K, Heise T, Heinemann L, Boss AH. Inhaled Technosphere® insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes. J Diabetes Sci Technol 2008;2(2):2005-212
   Google Scholar
• Rave K, Potocka E, Boss AH, Pharmacokinetics and linear exposure of AFRESA™ compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab 2009;11(7):715-20
   PubMed Web of Science ®Google Scholar
• Raskin P, Heller S, Honka M, Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial. Diabetes Obes Metab 2012;14(2):163-73
   PubMed Web of Science ®Google Scholar
• Rossiter A, Amin N, Harris R, Pulmonary safety of inhaled Technosphere® Insulin therapy in adults with diabetes using high-resolution computerized tomography of the chest. Diabetologia 2009;52(S1):abstract #921
   Google Scholar
• Skyler JS, Hollander PA, Jovanovic L, Safety and efficacy of inhaled human insulin (Exubera®) during discontinuation and readministration of therapy in adults with type 1 diabetes: a 3-year randomized controlled trial. Diabetes Res Clin Pract 2008;82(2):238-46
   PubMed Web of Science ®Google Scholar
• Neumiller JJ, Campbell RK. Technosphere(R) insulin: an inhaled prandial insulin product. BioDrugs 2010;24(3):165-72
   PubMed Web of Science ®Google Scholar
• Forst T, Hohberg C, Schöndorf T, Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen device. Diabetes Technol Ther 2009;11(2):87-92
   PubMed Web of Science ®Google Scholar
• Patton JS, Bukar JG, Eldon MA. Clinical Pharmacokinetics and Pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004;43(12):781-801
   PubMed Web of Science ®Google Scholar
• Rave K BS, Heinemann L, Sha S, Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005;28(5):1077-82
   PubMed Web of Science ®Google Scholar
• Quattrin T, Bélanger A, Bohannon NJ, Schwartz SL; Group. EPIS. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27(11):2622-7
   PubMed Web of Science ®Google Scholar
• Hollander PA, Blonde L, Rowe R, Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27(10):2356-62
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Cefalu WT, Hollander PA, Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes. Diabetes Care 2008;31(9):1723-8
   PubMed Web of Science ®Google Scholar
• Skyler JS, Jovanovic L, Klioze S, Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care 2007;30:579-85
   PubMed Web of Science ®Google Scholar
• Hollander P, Krasner A, Klioze S, Body weight changes associated with insulin therapy: a retrospective pooled analysis of inhaled human insulin (Exubera 1) versus subcutaneous insulin in five controlled phase 3 trials. Diabetes Care 2007;30:2508-10
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Foyt H, Klioze S, Inhaled human insulin (Exubera®) therapy shows sustained efficacy and is well tolerated over a 2-year period in patients with type 2 diabetes (T2DM). Diabetes Metab 2006;55(S1):A109-OR
   Google Scholar
• Alabraba V, Farnsworth A, Leigh R, Exubera inhaled insulin in patients with type 1 and type 2 diabetes: the first 12 months. Diabetes Technol Ther 2009;11(7):427-30
   PubMed Web of Science ®Google Scholar
• Van Alfen-van der Velden A, Noordam C, De Galan BE, Successful treatment of severe subcutaneous insulin resistance with inhaled insulin therapy. Pediatr Diabetes 2010;11(6):380-2
   PubMed Web of Science ®Google Scholar
• Hollander PA, Cefalu WT, Mitnick M, Titration of inhaled human insulin (Exubera) in a treat-to-target regimen for patients with type 2 diabetes. Diabetes Technol Ther 2010;12(3):185-91
   PubMed Web of Science ®Google Scholar
• Harper NJ, Gray S, De Groot J, The design and performance of the exubera pulmonary insulin delivery system. Diabetes Technol Ther 2007;9(Suppl 1):S16-27
   PubMedGoogle Scholar
• Rosenstock J, Cappelleri J, Bolinder B, Gerber R. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004;27(6):1318-23
   PubMed Web of Science ®Google Scholar
• Gerber RA CJ, Kourides IA, Gelfand RA. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care 2001;24(9):1556-9
   PubMed Web of Science ®Google Scholar
• Wollmer P, Pieber TR, Gall MA, Brunton S. Delivering needle-free insulin using AERx® iDMS (Insulin Diabetes Management System) technology. Diabetes Technol Ther 2007;9(Suppl 1):S57-64
   PubMedGoogle Scholar
• Cramer JA, Okikawa J, Bellaire S, Clauson P. Compliance with inhaled insulin treatment using the AERx iDMS insulin diabetes management system. Diabetes Technol Ther 2004;6(6):800-7
   PubMedGoogle Scholar
• Mudaliar S. Inhaled insulin using AERx insulin diabetes management system (AERx iDMS). Expert Opin Investig Drugs 2007;16(10):1673-81
   PubMed Web of Science ®Google Scholar
• Brunner GA, Balent B, Ellmerer M, Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia 2001;44(3):305-8
   PubMed Web of Science ®Google Scholar
• Moses RG, Bartley P, Lunt H, Safety and efficacy of inhaled insulin (AERx® iDMS1) compared with subcutaneous insulin therapy in patients with type 1 diabetes: 1-year data from a randomized, parallel group trial. Diabet Med 2009;26(3):260-7
   PubMed Web of Science ®Google Scholar
• Hermansen K, Rönnemaa T, Petersen AH, Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 2004;27(1):162-7
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Muchmore D, Swanson D, Schmitke J. AIR inhaled insulin system: a novel insulin-delivery system for patients with diabetes. Expert Rev Med Devices 2007;4(5):683-92
   PubMed Web of Science ®Google Scholar
• Ellis SL, Gemperline KA, Garg SK. Review of phase 2 studies utilizing the AIR particle technology in the delivery of human insulin inhalation powder versus subcutaneous regular or lispro insulin in subjects with type 1 or type 2 diabetes. Diabetes Technol Ther 2007(Suppl 1):S48-56
   Google Scholar
• Muchmore DB, Silverman B, De La Peña A, Tobian J. The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic data. Diabetes Technol Ther 2007(Suppl 1):S41-7
   Google Scholar
• de La Peña A, Seger M, Rave K, AIR insulin capsules of different dose strengths may be combined to yield equivalent pharmacokinetics and glucodynamics. Diabetes Technol Ther 2009(Suppl 2):S75-80
   Google Scholar
• Gross JL, Nakano M, Colon-Vega G, Initiation of prandial insulin therapy with AIR inhaled insulin or insulin lispro in patients with type 2 diabetes: a randomized noninferiority trial. Diabetes Technol Ther 2009(Suppl 2):S27-34
   Google Scholar
• Gross JL, Nakano M, Colon-Vega G, Two-year efficacy and safety of AIR inhaled insulin in patients with type 1 diabetes: an open-label randomized controlled trial. Diabetes Technol Ther 2009(Suppl 2):S5-16
   Google Scholar
• Bergenstal RM, Freemantle N, Leyk M, Does availability of AIR insulin increase insulin use and improve glycemic control in patients with type 2 diabetes? Diabetes Technol Ther 2009;11(Suppl 2):S45-52
   PubMedGoogle Scholar
• Hayes RP, Muchmore D, Schmitke J. Effect of inhaled insulin on patient-reported outcomes and treatment preference in patients with type 1 diabetes. Curr Med Res Opin 2007;23(2):435-42
   PubMed Web of Science ®Google Scholar
• Kapitza C HT, Fishman RS, Shapiro DA, Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol. Diabetes Technol Ther 2004;6(2):119-27
   PubMedGoogle Scholar
• Kim D, Mudaliar S, Chinnapongse S, Dose-response relationships of inhaled insulin delivered via the aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes. Diabetes Care 2003;26(10):2842-7
   PubMed Web of Science ®Google Scholar
• Perera AD, Kapitza C, Nosek L, Absorption and metabolic effect of inhaled insulin intrapatient variability after inhalation via the aerodose insulin inhaler in patients with type 2 diabetes. Diabetes Care 2002;25(12):2276-81
   PubMed Web of Science ®Google Scholar
• Baxter Presents Phase I Inhaled Insulin Study Results at Respiratory Drug Delivery Conference. Baxter International, Inc. France. 2007. Available from: www.baxter.com/press_room/press_releases/2007/04-20-07-promaxx.html [Last accessed 18 September 2012]
   Google Scholar
• White S, Brown LR, McGeehan J, The science and technology of the PROMAXX biotechnology platform. RDD Eur 2007;1:51-8
   Google Scholar
• Rashba-Step J. Efficient pulmonary delivery of biological molecules as PROMAXX microspheres. In: ONdrugDelivery, editor. Pulmonary drug delivery: new perspectives on inhalers. ONdrugDelivery; Hove: 2007. p. 21-4
   Google Scholar
• Heise T, Brugger A, Cook C, PROMAXX® inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler. Diabetes Obes Metab 2009;11(5):455-9
   PubMed Web of Science ®Google Scholar
• Siekmeir R, Scheuch G. Inhaled Insulin - does it become reality? J Physiol Pharmacol 2008;59(6):81-113
   Google Scholar
• Stote R, Miller M, Marbury T, Enhanced absorption of Nasulin™, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjects. J Diabetes Sci Technol 2011;5(1):113-19
   PubMedGoogle Scholar
• Leary AC, Stote RM, Breedt HJ, Pharmacokinetics and pharmacodynamics of intranasal insulin administered to healthy subjects in escalating doses. Diabetes Technol Ther 2005;7(1):113-19
   Google Scholar
• Leary AC, Stote RM, Cussen K, Pharmacokinetics and pharmacodynamics of intranasal insulin administered to patients with type 1 diabetes: a preliminary study. Diabetes Technol Ther 2006;8(1):81-8
   PubMed Web of Science ®Google Scholar
• Stote R, Marbury T, Shi L, Comparison pharmacokinetics of two concentrations (0.7% and 1.0%) of Nasulin, an ultra-rapid-acting intranasal insulin formulation. J Diabetes Sci Technol 2010;4(3):603-9
   PubMedGoogle Scholar
• Leary AC, Dowling M, Cussen K, Pharmacokinetics and pharmacodynamics of intranasal insulin spray (Nasulin™) administered to healthy male volunteers: influence of the nasal cycle. J Diabetes Sci Technol 2008;2(6):1054-60
   PubMedGoogle Scholar
• CPEX Pharmaceuticals, Inc. Form 10-K Annual report: United States Securities and Exchange Commission. Washington, D.C. 20549. 2010. Available from: http://www.faqs.org/sec-filings/110331/CPEX-Pharmaceuticals-Inc_10-K/ [Last accessed 30 July 2012]
   Google Scholar
• Illum L. Nasal drug delivery — recent developments and future prospects. J Control Release 2012;161(2):254-63
   PubMed Web of Science ®Google Scholar
• CPEX Pharmaceuticals Web Page. Available from: http://www.cpexpharma.com [Last accessed 30 July 2012]
   Google Scholar
• Marina Biotech Web Page. Available from: http://www.marinabio.com/ [Last accessed 30 July 2012]
   Google Scholar
• Benedict C, Frey Ii WH, Schiöth HB, Intranasal insulin as a therapeutic option in the treatment of cognitive impairments. Exp Gerontol 2011;46(2–3):112-15
   PubMed Web of Science ®Google Scholar
• Schiöth HB, Frey WH, Brooks SJ, Benedict C. Insulin to treat Alzheimer's disease: just follow your nose? Expert Rev Clin Pharmacol 2011;5(1):17-20
   Google Scholar
• Craft S, Baker LD, Montine TJ, Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69(1):29-38
   PubMed Web of Science ®Google Scholar
• Arbit E, Kidron M. Oral insulin: the rationale for this approach and current developments. J Diabetes Sci Tech 2009;3(3):562-7
   PubMedGoogle Scholar
• Woitiski CB, Sarmento B, Carvalho RA, Facilitated nanoscale delivery of insulin across intestinal membrane models. Int J Pharm 2011;412(1–2):123-31
   PubMed Web of Science ®Google Scholar
• Diabetology Web Page. Available from: http://www.diabetology.co.uk/ [Last accessed 8 July 2012]
   Google Scholar
• Luzio SD, Dunseath G, Lockett A, The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. Diabetes Obes Metab 2010;12(1):82-7
   PubMed Web of Science ®Google Scholar
• Sabetsky V, Ekblom J. Insulin: a new era for an old hormone. Pharmacol Res 2010;61(1):1-4
   PubMed Web of Science ®Google Scholar
• Oramed Web Page. Available from: http://www.oramed.com/ [Last accessed 8 July 2012]
   Google Scholar
• Eldor R, Arbit E, Miteva Y, Oral Insulin: Type I Diabetes (T1DM) Patient Response Upon Preprandial Administration. American Diabetes Association. 70th Scientific Session; 2010
   Google Scholar
• Kidron M, Eldor R, Miteva Y, Extended exposure to an oral insulin formulation yields decreased insulin secretion in type II diabetes subjects. Diabetes Technology Meeting; 2010
   Google Scholar
• Emisphere Technologies Web Page. Available from: http://www.emisphere.com/index.html [Last accessed 8 July 2012]
   Google Scholar
• Park K, Kwon IC, Park K. Oral protein delivery: current status and future prospect. React Funct Polym 2011;71(3):280-7
   Web of Science ®Google Scholar
• Hoffman A, Qadri B. Eligen insulin - a system for the oral delivery of insulin for diabetes. IDrugs 2008;11(6):433-41
   PubMed Web of Science ®Google Scholar
• Emisphere Technologies Annual Report and Proxy. 2011. Available from: http://www.annualreports.com/HostedData/AnnualReports/PDF/EMIS2011.pdf [Last accessed 26 July 2012]
   Google Scholar
• BOWS Pharmaceuticals AG Web Page. Available from: http://www.bowspharma.com/ [Last accessed 8 July 2012]
   Google Scholar
• ClinicTrials.gov Web Page. Available from: http://clinicaltrials.gov/ [Last accessed 9 August 2012]
   Google Scholar
• Merrion Pharmaceuticals Web Page. Available from: http://www.merrionpharma.com/ [Last accessed 8 July 2012]
   Google Scholar
• Clinic Trials at Novo Nordisk Web Page. Available from: http://www.novonordisk-trials.com/ [Last accessed 25 July 2012]
   Google Scholar
• Diasome Pharmaceuticals Web Page. Available from: http://www.diasome.com/ [Last accessed 9 July 2012]
   Google Scholar
• Geho WB, Geho HC, Lau JR, Gana T. Hepatic-directed vesicle insulin: a review of formulation development and preclinical evaluation. J Diabetes Sci Technol 2009;3(6):1451-9
   PubMedGoogle Scholar
• Schwartz S, Geho B, Rosenberg L, Lau J. Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus. Conshohocken, PA: Diasome Pharmaceuticals and San Antonio, TX: Diabetes Glandular Research Center. 2008. Available from: http://www.diasome.com/docs/FINAL%202009%20ADA%20Poster.pdf [Last accessed 30 July 2012]
   Google Scholar
• Schwartz S, Geho B, Rosenberg L, Lau J. A Two-Week Randomized Active Comparator Study of Two HDV-Insulin Routes (SC and Oral) and SC Human Insulin in Patients With Type 1 Diabetes Mellitus (417-P). Poster session presented at: 68th Annual American Diabetes Association Meeting; 6 – 10 Jun 2008; San Francisco, Ca
   Google Scholar
• Biocon Biopharmaceuticals Web Page. Available from: http://www.biocon.com/ Last [accessed 9 July 2012]
   Google Scholar
• Iyer H, Khedkar A, Verma M. Oral insulin – a review of current status. Diabetes Obes Metab 2010;12(3):179-85
   PubMed Web of Science ®Google Scholar
• Access Pharmaceuticals, Inc. Web Page. Available from: http://www.accesspharma.com [Last accessed 1 August 2012]
   Google Scholar
• Heinemann L. New ways of insulin delivery. Int J Clin Pract 2012;66:35-9
   Google Scholar
• Generex Biotechnology Corp. Web Page. Available from: http://www.generex.com/index.php [Last accessed 23 July 2012]
   Google Scholar
• Khafagy E-S, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliv Rev 2007;59:1521-46
   PubMed Web of Science ®Google Scholar
• Kumria R, Goomber G. Emerging trends in insulin delivery: buccal route. J Diabetol 2011;2(1):1-9
   Google Scholar
• Kinesh VP, Neelam DP, Punit BP, Novel approaches for oral delivery of insulin and current status of oral insulin products. IJPSN 2010;3(3):1057-64
   Google Scholar
• Monosol Rx Web Page. Available from: http://www.monosolrx.com/ [Last accessed 3 August 20102]
   Google Scholar
• Midatech Ltd. Available from: http://www.midatechgroup.com/ [Last accessed 3 August 2012]
   Google Scholar
• Zubaerova DK, Larionova NI. Noninvasive insulin delivery systems. biochemistry (Moscow) supplement series B. Biomed Chem 2008;2(4):346-55
   Google Scholar
• Jain A, Dhote V, Dhongade H, Microneedles: a revolution of transdermal drug delivery. PR 2008;6(3)
   Google Scholar
• Shivanand P, Binal P, Viral D. Microneedles: progress in developing new technology for painless drug delivery. IJPTR 2009;1(4):1279-82
   Google Scholar
• Nordquist L, Roxhed N, Griss P, Stemme G. Novel microneedle patches for active insulin delivery are efficient in maintaining glycaemic control: an initial comparison with subcutaneous administration. PR 2007;24(7):1381-8
   Google Scholar
• Silpi C, Manish B, Kumar TR. Microneedles in transdermal drug delivery: an unique painless option. IRJP 2011;2(4):72-8
   Google Scholar
• Drug Delivery in Diabetes: making Effective Treatment Tolerable. ONdrugDelivery Web Page. Available from: http://www.ondrugdelivery.com/publications/diabetes.pdf [Last accessed 18 July 2012]
   Google Scholar
• Shivanand P, Jigisha P, Kinjal P. Various emerging technologies in insulin delivery system. IJPRD 2009;1(8):1-6
   Google Scholar
• Anhalt H, Bohannon NJV. Insulin patch pumps: their development and future in closed-loop systems. Diabetes Technology & Therapeutics 2010;12(S1):S-51-S-8
   Google Scholar
• Valeritas, Inc. Web Page. Available from: http://www.valeritas.com/ [Last accessed 9 August 2012]
   Google Scholar
• V-Go Disposable Insulin Delivery Device. Valeritas, Inc. Available from: http://www.go-vgo.com/ [Last accessed 30 July 2012]
   Google Scholar
• Amin A, Shah T, Patel J, Gajjar A. Non Invasive Insulin - Annual Update on Non-Invasive Insulin Delivery Technologies. Drug Deliv Technol 2007;7(3):43-8. Available from: http://www.drugdeliverytech-online.com/drugdelivery/200803/?pg=43#pg43 [Last accessed 30 July 2012]
   Google Scholar
• Chen H, Zhu H, Zheng J, Iontophoresis-driven penetration of nanovesicles through microneedle-induced skin microchannels for enhancing transdermal delivery of insulin. J Control Release 2009;139:63-72
   PubMed Web of Science ®Google Scholar
• Polat BE, Hart D, Langer R, Blankschtein D. Ultrasound-mediated transdermal drug delivery: mechanisms, scope, and emerging trends. J Control Release 2011;152(3):330-48
   PubMed Web of Science ®Google Scholar
• Ogura M, Paliwal S, Mitragotri S. Low-frequency sonophoresis: current status and future prospects. Adv Drug Deliv Rev 2008;60(10):1218-23
   PubMed Web of Science ®Google Scholar
• Mitragotri S, Blankschtein D, Langer R. Ultrasound-mediated transdermal protein delivery. Science 1995;269(5225):850-3
   PubMed Web of Science ®Google Scholar
• Tezel A, Sens A, Tuchscherer J, Mitragotri S. Frequency dependence of sonophoresis. Pharm Res 2001;18(12):1694-700
   PubMed Web of Science ®Google Scholar
• Saroha K, Sharma B, Yadav B. Sonophoresis: an advanced tool in transdermal drug delivery system. IJCPR 2011;3(3):89-97
   Google Scholar
• Polat BE, Blankschtein D, Langer R. Low-frequency sonophoresis: application to the transdermal delivery of macromolecules and hydrophilic drugs. Expet Opin Drug Deliv 2010;7(12):1415-32
   PubMed Web of Science ®Google Scholar
• Mitragotri S. Synergistic effect of enhancers for transdermal drug delivery. Pharm Res 2000;17(11):1354-9
   PubMed Web of Science ®Google Scholar
• Transdermal Specialties, Inc. Web Page. Available from: http://www.transdermalspecialties.com [Last accessed 19 September 2012]
   Google Scholar
• Transdermal Specialties, Inc. 2012 Offering documents. Available from: http://www.transdermalspecialties.com/pdf/TSI_2012_ppm.pdf [Last accessed 9 August 2012]
   Google Scholar
• GlobeNewswire Web Page. Available from: http://www.globenewswire.com/ [Last accessed at 9 August 2012]
   Google Scholar
• Kulkarni PR, Yadav JD, Vaidya KA, Gandhi PP. Transferosomes: an emerging tool for transdermal drug delivery. IJPSR 2011;2(4):735-41
   Google Scholar
• Wadhwa S, Rawat S, Singhal S, Transferosome: a versatile tool for transdermal drug delivery. JPR 2012;5(1):610-15
   Google Scholar
• Kapsner P, Bergenstal R, Rendell M, Comparative efficacy and safety of Technosphere® insulin and a rapid-acting analog both given with glargine in subjects with T1DM in a 52-week study. Diabetologia 2009;52(S1):abstract #982
   Google Scholar
• Rosenstock J, Bergenstal R, Defronzo RA, Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. Diabetes Care 2008;31(11):2177-82
   PubMed Web of Science ®Google Scholar
• Tack CJ, Christov V, Galan BE, Randomized forced titration to different doses of Technosphere® insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes. J Diabetes Sci Technol 2008;2(1):47-57
   PubMedGoogle Scholar
• Petrucci R, Amin N, Lovertin P, Pulmonary function tests remain similar in patients who received technosphere insulin and in patients currently receiving standard antidiabetic therapy [abstract #919]. Diabetologia 2009;52(S1):S361
   Google Scholar
• Peyrot M, Rubin RR. Patient-reported outcomes in adults with type 2 diabetes using mealtime inhaled technosphere insulin and basal insulin versus premixed insulin. Diabetes Technol Ther 2011;13(12):1201-6
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR. Effect of technosphere inhaled insulin on quality of life and treatment satisfaction. Diabetes Technol Ther 2010;12(1):49-55
   PubMed Web of Science ®Google Scholar
• Heinemann L. The failure of exubera: are we beating a dead horse? J Diabetes Sci Technol 2008;2(3):518-29
   PubMedGoogle Scholar
• Nektar Therapeutics Web Page. Available from: http://www.nektar.com/ Last [accessed 30 July 2012]
   Google Scholar
• Aradigm Corp. website. Available from: http://www.aradigm.com [Last accessed 30 July 2012]
   Google Scholar
• Alkermes Web Page. Available from: http://www.alkermes.com/ [Last accessed 30 July 2012]
   Google Scholar
• Aerogen Web Page. Available from: http://www.aerogen.com/ [Last accessed 30 July 2012]
   Google Scholar
• Aerogen, Inc. Form 10-K Annual report: United States Securities and Exchange Comission. Washington, D.C. 20549. 2005.Available from: http://www.getfilings.com/o0001104659-05-016717.html [Last accessed 30 July 2012]
   Google Scholar
• Abbott Web Page. Available from: http://www.abbott.com/ [Last accessed 30 July 2012]
   Google Scholar
• Vectura Web Page. Available from: http://www.vectura.com/ [Last accessed 30 July 2010]
   Google Scholar
• MicroDose Therapeutx Web Page. Available from: http://mdtx.com/ [Last accessed 30 July 2012]
   Google Scholar
• Siekmeier R, Scheuch G. Diabetes treatment by inhalation of insulin - shine and decline of a novel type of therapy. In: Esquinas AM, editor. Applied technologies in pulmonary medicine. Karger; Basel: 2011. p. 77-83
   Google Scholar
• Coremed Web Page. Available from: http://www.coremedusa.com/ [Last accessed 30 July 2012]
   Google Scholar
• BioSante Pharmaceuticals Web Page. Available from: http://www.biosantepharma.com/ [Last accessed 30 July 2012]
   Google Scholar
• Biopharmaceutiques Web Page. Available from: http://www.biopharmaceutiques.com/ [Last accessed 8 July 2012]
   Google Scholar